IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, they create value through the combination of the world’s largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property.
They are building the world’s most extensive and comprehensive IMIDs database of novel content. Their focus in on six common IMIDs: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Psoriatic Arthritis, and Systemic Lupus Erythematosus.
All resident associate companies on the HudsonAlpha campus are independently owned and operated.